The Ring Study

The Ring Study, a clinical trial led by the International Partnership for Microbicides, is designed to determine whether IPM's monthly vaginal ring that delivers the ARV drug dapivirine helps prevent HIV infection in women and is safe for long-term use.

The first efficacy study of a vaginal ring for HIV prevention, The Ring Study is fully enrolled with 1,959 women ages 18-45 across six sites in South Africa and one site in Uganda.

The dapivirine ring licensure program

The Ring Study is part of IPM’s broader Dapivirine Ring Licensure Program.

The full licensure program also includes ASPIRE, a "sister" efficacy and safety study of the dapivirine ring led by IPM's clinical trial partner, the US NIH-funded Microbicide Trials Network (MTN). ASPIRE completed participant follow-up of 2,629 women ages 18-45 across 15 sites in Malawi, South Africa, Uganda, and Zimbabwe. Together, the two "sister" Phase III studies involve thousands of women volunteers across Africa.

In February 2016, The Ring Study and ASPIRE found that the monthly dapivirine ring can safely help prevent HIV infection in women, with differences in efficacy by age and level of use. 

Learn more about the Phase III results and the next steps for The Ring Study.

The ring

IPM’s ring uses a novel delivery method that slowly releases the ARV dapivirine over time, and is designed to remain in place for at least one month to provide sustained, discreet and easy-to-use protection against HIV. 

Learn more about IPM.